Novartis feels sales erosion in the final quarter due to copycats
Keystone-SDA
Novartis revenues slowed to a standstill in the final quarter of 2025. The Swiss pharmaceutical firm presents a mixed outlook for the current year.
+Get the most important news from Switzerland in your inbox
Novartis sales grew just 1% year-on-year to $13.3 billion in the last three months of 2025. At constant exchange rates, this represents a 1% decrease. The pace of revenue growth has slowed considerably after double-digit growth in each of the first two quarters.
For the full year 2025, Novartis generated sales of CHF54.5 billion (+8%). The company achieved the net growth in the high single-digit percentage range forecast by management.
The bottom line was an annual profit of CHF14 billion after just under CHF12 billion in 2024.
+ Read how Trump upended the Swiss pharma industry
Shareholders will receive an increased dividend of CHF 3.70 from CHF 3.50.
In the current year, Novartis management is aiming for sales growth in the low single-digit percentage range at constant exchange rates. Core operating profit is expected to decline in the low single-digit percentage range.
More
More
Science podcast: the AI revolution in drug development
Adapted from German by AI/mga
We select the most relevant news for an international audience and use automatic translation tools to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication.
Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.
If you have any questions about how we work, write to us at english@swissinfo.ch
